Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Withdrawn 1Unknown 1Terminated 1Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 1

Interventions

Paclitaxel 28Trastuzumab 22Cyclophosphamide 21Doxorubicin 14Docetaxel 14Carboplatin 11exemestane 10Radiotherapy 10Letrozole 10Capecitabine 10pembrolizumab 8Lapatinib 8Fulvestrant 8Neoadjuvant Therapy 6Goserelin 6Bevacizumab 6Anastrozole 6pertuzumab 5palbociclib 5eribulin 5abemaciclib 5Therapeutics 5Magnetic Resonance Spectroscopy 5Epirubicin 5Chemotherapy, Adjuvant 5Aromatase Inhibitors 5tucatinib 4Vinorelbine 4Taxes 4Tamoxifen 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Breast Neoplasms × onapristone × Clear all
NCT06938711 2025-04-22

A Rollover Protocol of Elacestrant, in Combination With Onapristone, for Patients With ER+, PR+, HER2- Advanced or Metastatic Breast Cancer

Context Therapeutics Inc.

Phase 1/2 Withdrawn
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡